Arrowhead Research reported $522.31M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
Agios Pharmaceuticals USD 1.37B 96.97M Jun/2025
Alnylam Pharmaceuticals USD 250.59M 135.16M Jun/2025
Arrowhead Research USD 522.31M 161.91M Jun/2025
Incyte USD 4.17B 503.34M Jun/2025
Ionis Pharmaceuticals USD 631.72M 156M Jun/2025
Ligand Pharmaceuticals USD 828.53M 32.99M Jun/2025
Merck USD 49.06B 725M Jun/2025
Moderna USD 9.4B 667M Jun/2025
Novartis USD 42.05B 3.6B Jun/2025
Sarepta Therapeutics USD 1.36B 214.66M Jun/2025
TG Therapeutics USD 276.43M 39.14M Jun/2025
Ultragenyx Pharmaceutical USD 151.29M 7.04M Jun/2025
Vertex Pharmaceuticals USD 17.18B 679.1M Jun/2025
Xencor USD 620.35M 19.52M Jun/2025